None of the patients had been fully vaccinated against severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). The analyzed endpoint was in-hospital mortality from any cause. This study was designed to assess the mortality rate in the group of patients with both STEMI and COVID-19 and to compare baseline characteristics, the angiographic view, and procedural and clinical outcomes between survivors and non-survivors. Anonymized data were gathered retrospectively. The ward existed from Octoto Ap(exactly 6 months). This was a single-center, retrospective study of 25 patients admitted to a multi-specialist hospital where a cardiology ward for COVID-19 patients was established. Moreover, the present study aimed to examine the association between the GRACE risk score and in-hospital mortality in this group of patients, which, to our best knowledge, has not been done so far. Īs there are limited reports on patients with STEMI and COVID-19 treated with percutaneous coronary intervention (PCI), we aimed to describe their demographic, angiographic and periprocedural characteristics along with their clinical outcomes. In others, fibrinolytic therapy was the main treatment strategy so there is no information regarding coronary arteries. stress-induced cardiomyopathy) or high thrombus burden.

Sparse reports of cardiac catheterization in patients with concomitant COVID-19 reveal a variety of angiographic findings in patients with ACS including obstructive coronary disease (type 1 myocardial infarction), angiographically normal epicardial arteries (e.g. The original GRACE data did not include patients with concomitant SARS-CoV-2 infection. There are eight parameters used to calculate the Global Registry of Acute Coronary Events (GRACE) risk score – age, heart rate, systolic blood pressure, initial creatinine level, Killip class, pre-hospital cardiac arrest, elevated cardiac markers and ST-segment elevation or depression – which are evaluated to calculate the risk of in-hospital mortality. Prognostic scoring systems including the Global Registry of Acute Coronary Events (GRACE) risk score and thrombolysis in myocardial infarction (TIMI) risk score have been reported to be useful in predicting in-hospital and long-term mortality among patients with ACS. These actions include prolonged monitoring of basic vital parameters such as electrocardiogram (ECG), SaO 2, blood pressure or delayed discharge after myocardial infarction. Selecting the group of patients with an unfavorable prognosis makes it possible to take actions that can potentially prevent the occurrence of adverse events. Īll ST-segment elevation myocardial infarction (STEMI) patients should undergo an early assessment of both short-term risk on admission and long-term risk at discharge. Notably, patients with COVID-19 and ACS have rarely been described in reports. Systemic viral infections may generate plaque rupture and thrombosis. Acute coronary syndromes (ACS) remained the leading cause of death and disability all over the world. The GRACE risk score is a good predictor of in-hospital mortality in patients presenting with STEMI with concomitant COVID-19.Ĭardiovascular complications develop frequently in patients with coronavirus disease 2019 (COVID-19). A score of 176 was identified as the optimal cut-off with a sensitivity of 92% and specificity of 69%. In ROC analysis, GRACE score predicted in-hospital death with an AUC of 0.788 (95% CI: 0.6–0.98, p = 0.014).

There was a higher GRACE score in the non-survivor group (mean ± SD 210 ☓5 vs. Postprocedural TIMI 3 flow grade was less frequently observed in this group (p = 0.039). Non-survivors had elevated high-sensitivity C-reactive protein (hsCRP) (p = 0.026) and D-dimer (p = 0.042) and reduced left ventricular ejection fraction (30 ☙ vs. They were treated with percutaneous coronary intervention and 12 (48%) of them died.

Twenty-five patients, of whom 23 (92%) were men, with confirmed STEMI and COVID-19, with a median age of 70 years and high comorbidity burden, were included in this study. Demographic, clinical and angiographic characteristics were compared between survivors and non-survivors.

This was a single-center, retrospective study of consecutive patients admitted to a multi-specialist hospital with confirmed ST-segment elevation myocardial infarction (STEMI) and treated with primary percutaneous coronary intervention. The aim of this study was to describe the clinical and angiographic characteristics alongside the prediction of in-hospital mortality using the GRACE risk score in this group. To date, there are only a few reports of ST-segment elevation type 1 myocardial infarction in patients with COVID-19. Acute coronary syndrome represents a major cause of mortality throughout the world.

Grace vs timi score